title: Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
abstract: Purpose Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combined with ipilimumab (a cytotoxic T-lymphocyte antigen-4 checkpoint inhibitor), have not been reported in this rare melanoma subtype. Patients and Methods Data were pooled from 889 patients who received nivolumab monotherapy in clinical studies, including phase III trials; 86 (10%) had mucosal melanoma and 665 (75%) had cutaneous melanoma. Data were also pooled for patients who received nivolumab combined with ipilimumab (n = 35, mucosal melanoma; n = 326, cutaneous melanoma). Results Among patients who received nivolumab monotherapy, median progression-free survival was 3.0 months (95% CI, 2.2 to 5.4 months) and 6.2 months (95% CI, 5.1 to 7.5 months) for mucosal and cutaneous melanoma, with objective response rates of 23.3% (95% CI, 14.8% to 33.6%) and 40.9% (95% CI, 37.1% to 44.7%), respectively. Median progression-free survival in patients treated with nivolumab combined with ipilimumab was 5.9 months (95% CI, 2.8 months to not reached) and 11.7 months (95% CI, 8.9 to 16.7 months) for mucosal and cutaneous melanoma, with objective response rates of 37.1% (95% CI, 21.5% to 55.1%) and 60.4% (95% CI, 54.9% to 65.8%), respectively. For mucosal and cutaneous melanoma, respectively, the incidence of grade 3 or 4 treatment-related adverse events was 8.1% and 12.5% for nivolumab monotherapy and 40.0% and 54.9% for combination therapy. Conclusion To our knowledge, this is the largest analysis of data for anti-programmed death-1 therapy in mucosal melanoma to date. Nivolumab combined with ipilimumab seemed to have greater efficacy than either agent alone, and although the activity was lower in mucosal melanoma, the safety profile was similar between subtypes.
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Sandra P
authors.initials: SP
authors.lastname: D'Angelo
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: James
authors.initials: J
authors.lastname: Larkin
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Sosman
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Celeste
authors.initials: C
authors.lastname: Lebbé
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Brady
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Bart
authors.initials: B
authors.lastname: Neyns
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Henrik
authors.initials: H
authors.lastname: Schmidt
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Jessica C
authors.initials: JC
authors.lastname: Hassel
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Paul
authors.initials: P
authors.lastname: Lorigan
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Kerry J
authors.initials: KJ
authors.lastname: Savage
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Wilson H
authors.initials: WH
authors.lastname: Miller
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Peter
authors.initials: P
authors.lastname: Mohr
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Ivan
authors.initials: I
authors.lastname: Marquez-Rodas
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Julie
authors.initials: J
authors.lastname: Charles
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Martin
authors.initials: M
authors.lastname: Kaatz
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Mario
authors.initials: M
authors.lastname: Sznol
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Weber
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Alexander N
authors.initials: AN
authors.lastname: Shoushtari
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Mary
authors.initials: M
authors.lastname: Ruisi
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Joel
authors.initials: J
authors.lastname: Jiang
authors.affiliation: Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Jedd D
authors.initials: JD
authors.lastname: Wolchok
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D009092:Mucous Membrane; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab; D000077594:Nivolumab